Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Genentech receives FDA approval for updated Vabysmo (faricimab-svoa) label extending macular edema treatment beyond six months
Antibody, ophthalmology, bispecific antibody, macular edema, retinal vein occlusion, VEGF inhibitor - Read more

Gilead, Kymera Therapeutics exercise option on CDK2 molecular glue degrader for $45M, $665M milestones
Licensing deal, oncology, small molecule, milestone payments - Read more

Boehringer Ingelheim hands Click Therapeutics marketing rights to schizophrenia PDT CT-155, $50M investment
Licensing deal, neurological, digital health, milestone payments - Read more

Roche, C4 Therapeutics expand molecular glue partnership with $20M upfront, over $1B milestones
Research collaboration, oncology, targeted protein degradation, milestone payments - Read more

Oxford BioTherapeutics, Bristol Myers Squibb collaborate on T-cell engager therapies for solid tumors
Research collaboration, oncology, T-cell engager, milestone payments - Read more

Nxera Pharma, Eli Lilly achieve second development milestone in diabetes collaboration, up to $694M potential milestones
Research collaboration, metabolic diseases, small molecule, GPCR targeting, milestone payments - Read more

Daiichi Sankyo, Imagene AI partner on ADC biomarker discovery using multimodal platform, terms undisclosed
Research collaboration, oncology, AI/ML, antibody, biomarker discovery - Read more

Boehringer Ingelheim, BioNTech partner on DLL3-targeting and PD-L1/VEGF combination therapy for lung cancer
Research collaboration, oncology, antibody, clinical trials - Read more

Boston Oncology, Xuanzhu Biopharmaceutical license breast and lung cancer treatments for $100M+ milestones
Licensing deal, oncology, small molecule, milestone payments - Read more

Most clinical accounting teams spend weeks chasing vendor estimates and updating spreadsheets just to close a single period. There’s a faster way—and you can watch it happen live.

Join Auxilius on April 28th at 2PM ET as we walk through a real, end-to-end period close in real time. You’ll see exactly how leading biopharmas have cut their close cycle while improving accuracy and audit readiness.

Essential for Corporate Controllers, VPs of Finance, and FP&A leaders responsible for clinical trial accounting and close. Save your spot now.

Invivyd prepares VMS063 antibody targeting fusion protein for Ph1 testing in measles treatment and prevention
Antibody, infectious disease, monoclonal antibody, measles, fusion protein target, prevention therapy - Read more

Zentalis Pharmaceuticals selects 400mg dose for azenosertib (WEE1 inhibitor) Ph2 trial in platinum-resistant ovarian cancer
Small molecule, cancer, WEE1 inhibitor, ovarian cancer, platinum-resistant - Read more

Avalyn Pharma plans IPO, developing inhalable IPF treatments for lung disease
Rare disease, small molecule, inhalable formulations, clinical-stage - Read more

Basilea Pharmaceutica raises $6M CARB-X funding for antibiotic BAL2420 clinical development
Infectious disease, antibiotic, small molecule, clinical-stage - Read more

Oricell Therapeutics raises $110M pre-IPO financing, accelerating solid tumor CAR-T development
Cancer, CAR-T therapy, solid tumor, clinical-stage, platform technology - Read more

BDC launches $150M Life Sciences Venture Fund for early-stage Canadian companies
Venture capital, life sciences, therapeutics, medical technology - Read more

Eli Lilly launches obesity pill Foundayo at $149, intensifying GLP-1 competition with Novo Nordisk's Wegovy
Small molecule, obesity, competitive, strategic - Read more

Innovent Biologics' CDMO Altruist gets China license for first 20,000-liter biologics production plant in Hangzhou
Biologics, operational, strategic, manufacturing expansion - Read more

FDA removes partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab cancer treatment
Bispecific antibody, oncology, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Federal judge rules HHS must face 19-state lawsuit challenging RFK Jr.'s agency restructuring and layoffs
Regulatory, operational, strategic, major transaction - Read more

RFK Jr. launches health podcast targeting pharma industry "hypocrisy" and government health "corruption"
Vaccines, infectious disease, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here